JP2009530235A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530235A5
JP2009530235A5 JP2008558610A JP2008558610A JP2009530235A5 JP 2009530235 A5 JP2009530235 A5 JP 2009530235A5 JP 2008558610 A JP2008558610 A JP 2008558610A JP 2008558610 A JP2008558610 A JP 2008558610A JP 2009530235 A5 JP2009530235 A5 JP 2009530235A5
Authority
JP
Japan
Prior art keywords
composition
stem cell
administered
neural stem
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000427 external-priority patent/WO2007106987A1/en
Publication of JP2009530235A publication Critical patent/JP2009530235A/ja
Publication of JP2009530235A5 publication Critical patent/JP2009530235A5/ja
Pending legal-status Critical Current

Links

JP2008558610A 2006-03-17 2007-03-16 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン Pending JP2009530235A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78350006P 2006-03-17 2006-03-17
US78913206P 2006-04-05 2006-04-05
US86266906P 2006-10-24 2006-10-24
PCT/CA2007/000427 WO2007106987A1 (en) 2006-03-17 2007-03-16 Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010056766A Division JP2010138203A (ja) 2006-03-17 2010-03-12 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン

Publications (2)

Publication Number Publication Date
JP2009530235A JP2009530235A (ja) 2009-08-27
JP2009530235A5 true JP2009530235A5 (https=) 2010-04-30

Family

ID=38521972

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008558610A Pending JP2009530235A (ja) 2006-03-17 2007-03-16 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
JP2008558609A Pending JP2009530234A (ja) 2006-03-17 2007-03-16 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン
JP2010056766A Pending JP2010138203A (ja) 2006-03-17 2010-03-12 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
JP2010056764A Pending JP2010138202A (ja) 2006-03-17 2010-03-12 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2008558609A Pending JP2009530234A (ja) 2006-03-17 2007-03-16 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン
JP2010056766A Pending JP2010138203A (ja) 2006-03-17 2010-03-12 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
JP2010056764A Pending JP2010138202A (ja) 2006-03-17 2010-03-12 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン

Country Status (8)

Country Link
US (3) US8143220B2 (https=)
EP (2) EP2004212A4 (https=)
JP (4) JP2009530235A (https=)
KR (2) KR20080103108A (https=)
AU (2) AU2007229301B2 (https=)
CA (2) CA2643502A1 (https=)
IL (2) IL193857A0 (https=)
WO (2) WO2007106987A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106987A1 (en) 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
US20090261690A1 (en) * 2006-09-25 2009-10-22 Tomoaki Mashimo Ultrasonic wave handling device and a microscopic in-tube inspection system
EP2190453A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
JP2012522005A (ja) * 2009-03-26 2012-09-20 ヘンリー フォード ヘルス システム 神経損傷および神経変性疾患後の神経学的転帰を改善する方法
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) * 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
WO2013112002A1 (ko) * 2012-01-27 2013-08-01 의료법인 성광의료재단 뇌 손상 증세의 경감 또는 완화에 대한 바이오마커
WO2014063071A1 (en) 2012-10-18 2014-04-24 Neuralight Hd, Llc Treatment of depression and ptsd
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
JP6879297B2 (ja) * 2016-04-13 2021-06-02 味の素株式会社 加齢に伴う身体機能低下もしくは身体機能障害、または加齢に伴う精神機能低下もしくは精神機能障害の抑制または改善用組成物

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
EP0441889A1 (fr) 1988-11-07 1991-08-21 Commission des Communautés Européennes Hormone de croissance humaine modifiee
US5128242A (en) 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0467279A3 (en) 1990-07-18 1992-08-05 Takeda Chemical Industries, Ltd. Polypeptides having c-amp producing activity
US5521069A (en) 1990-08-10 1996-05-28 Takeda Chemical Industries, Ltd. Genomic DNA exons having exons encoding human pituitary adenylate cyclase activity peptide with 38 amino acids residues(PACAP38) and a promoter thereof
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
US5723115A (en) 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク,インコーポレイテッド 配位子作用薬および拮抗薬の選択
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
DK0594669T4 (da) 1991-07-08 2008-04-21 Neurospheres Holdings Ltd Neurale progenitorceller, som reagerer på vækstfaktorer og kan formeres in vitro
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
WO1993003757A1 (en) 1991-08-16 1993-03-04 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5623050A (en) 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
US5253648A (en) 1991-10-11 1993-10-19 Spacelabs Medical, Inc. Method and apparatus for excluding artifacts from automatic blood pressure measurements
WO1993023067A1 (en) 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994009119A1 (en) 1992-10-16 1994-04-28 Neurospheres Ltd. Remyelination using neural stem cells
KR950704476A (ko) 1992-10-28 1995-11-20 브렌드 레이놀즈 생물학적 인자 및 신경 간세포(biological factors and neural stem cells)
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
CN1141058A (zh) 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 中枢神经系统干细胞的原位修饰和处理
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6239105B1 (en) 1994-03-31 2001-05-29 Barbara A. Brewitt Homeopathic preparations of purified growth hormone
WO1995029690A1 (en) 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US5795790A (en) 1994-07-20 1998-08-18 Cytotherapeutics, Inc. Method for controlling proliferation and differentiation of cells encapsulated within bioartificial organs
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5547143A (en) * 1994-08-24 1996-08-20 Alliedsignal Inc. Seat belt retractor with integrated load limiter
US6680295B1 (en) 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
JPH10505863A (ja) 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
FI971956L (fi) 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5547993A (en) 1995-10-24 1996-08-20 Mitsubishi Chemical Corporation Therapeutic agent for glaucoma
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU3492497A (en) 1996-06-21 1998-01-07 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
IT1284876B1 (it) 1996-08-07 1998-05-22 Applied Research Systems Hcg come inibitore della collagenasi
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
CA2301693A1 (en) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
WO1999022734A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
TW445295B (en) 1997-12-31 2001-07-11 Shiu Li Wei Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
FR2794473B1 (fr) 1999-06-03 2003-09-26 Centre Nat Rech Scient Procede de multiplication de cellules souches
US6618698B1 (en) 1999-08-12 2003-09-09 Quickturn Design Systems, Inc. Clustered processors in an emulation engine
US6395546B1 (en) 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
KR100358754B1 (ko) * 2000-02-14 2002-11-07 대한민국 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU7107301A (en) 2000-07-18 2002-01-30 Nichimo Co. Ltd. Stem cell reinforcing material
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
US6740163B1 (en) 2001-06-15 2004-05-25 Seagate Technology Llc Photoresist recirculation and viscosity control for dip coating applications
WO2002102988A2 (en) 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
AU2002355107A1 (en) 2001-07-19 2003-03-03 Thomson Licensing S.A. Robust reception of digital broadcast transmission
CA2364095C (en) 2001-07-20 2011-07-12 Neurostasis, Inc Production of radial glial cells
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
ITPR20010072A1 (it) 2001-10-26 2003-04-26 Firaco Srl Apparato e procedimento di sicurezza per veicoli di trasporto, in particolare aeromobili.
AU2003228050A1 (en) 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
WO2004011021A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
EP1633383A4 (en) 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US20070111932A1 (en) 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
CA2582567A1 (en) 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106987A1 (en) 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
US20100047233A1 (en) 2006-12-18 2010-02-25 Smith Mark A Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders
WO2008077085A1 (en) 2006-12-19 2008-06-26 Case Western Reserve University Brain-derived gonadotropins and cognition
US20080286234A1 (en) 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2009530235A5 (https=)
JP2009530234A5 (https=)
Papaspyropoulos et al. Modeling and targeting Alzheimer’s disease with organoids
Spagnolo et al. The management of patients with idiopathic pulmonary fibrosis
Zhang et al. Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model
Aujla et al. TH17 cells in asthma and inflammation
Hanson et al. Intranasal administration of CNS therapeutics to awake mice
Park et al. Human umbilical cord blood cell grafts for brain ischemia
D’Souza et al. Targeting the cholinergic system to develop a novel therapy for Huntington’s disease
EP2478901A3 (en) Neurogenic compounds
JP2010518164A5 (https=)
Ramos et al. Human insulin–induced lipoatrophy: a successful treatment with glucocorticoid
CN117617181B (zh) 一种系统性红斑狼疮小鼠模型的构建方法和应用
US9682078B2 (en) Compositions and methods for tissue engineering and cell based therapies
JP2014129405A5 (https=)
Tae et al. Neuronal injury and tumor necrosis factor-alpha immunoreactivity in the rat hippocampus in the early period of asphyxia-induced cardiac arrest under normothermia
CN109562145B (zh) 含胰岛素样生长因子-2的药物组合物及其应用
Xiong et al. Neuroprotection of erythropoietin and methylprednisolone against spinal cord ischemia-reperfusion injury
Lee et al. Human umbilical cord blood-derived mesenchymal stem cells improve neurological abnormalities of Niemann-Pick type C mouse by modulation of neuroinflammatory condition
JP2012502105A5 (https=)
CN119424478A (zh) 用于多聚谷氨酰胺(polyq)疾病的治疗
Alamy et al. Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features
Liu et al. The therapeutic effect of exosomes in type 2 diabetes mellitus and its complications
Zhang et al. Stem cell therapy in chronic periodontitis: Host limitations and strategies
Pocock et al. An open-label, prospective study evaluating the clinical and immunological effects of higher dose granulocyte colony–stimulating factor in ALS